Haw Par's basic earnings per share (Basic EPS) for the
six
months ended in Dec. 2025 was S$0.55.
Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2025 was S$1.20.
Haw Par's EPS (Diluted) for the
six
months ended in Dec. 2025 was S$0.55.
Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was S$1.20.
Haw Par's EPS without NRI for the
six
months ended in Dec. 2025 was S$0.55.
Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was 1.20.
During the past 12 months, Haw Par's average EPS without NRIGrowth Rate was 16.30% per year.
During the past 3 years, the average EPS without NRIGrowth Rate was 21.40% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 20.50% per year.
During the past 10 years, the average EPS without NRIGrowth Rate was 4.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.
During the past 13 years, Haw Par's highest 3-Year average EPS without NRI Growth Rate was 27.80% per year. The lowest was -17.50% per year. And the median was 5.30% per year.
Haw Par (SGX:H02) EPS (Basic) Explanation
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Haw Par EPS (Basic) Related Terms
Haw Par EPS (Basic) Historical Data
* Premium members only.
The historical data trend for Haw Par's EPS (Basic) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.
Haw Par's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as
EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was S$1.20
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Haw Par (SGX:H02) has a EPS (Basic) of S$1.20 as of Dec. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Haw Par and its competitors.
Is Haw Par's EPS (Basic) too high?
Haw Par's current EPS (Basic) is S$1.20. Overall, Haw Par has a GF Score™ of 95/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Haw Par's EPS (Basic) compare to LLY and JNJ?
Haw Par's EPS (Basic) of S$1.20 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Drug Manufacturers company?
A good EPS (Basic) depends on the Drug Manufacturers industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Haw Par and its competitors. Haw Par's current EPS (Basic) is S$1.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Haw Par stock overvalued right now?
Based on GuruFocus' analysis, Haw Par (SGX:H02) is currently considered Significantly Overvalued. The stock's GF Value™ is S$11.80, compared to a current price of S$16.03 — trading 35.8% above its estimated fair value. The current EPS (Basic) is S$1.20. Haw Par's overall GF Score™ is 95/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Haw Par (SGX:H02), the current EPS (Basic) is S$1.20 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Haw Par (SGX:H02) Overvalued in 2026?
Based on GuruFocus' analysis, Haw Par stock appears to be overvalued.
The current stock price of S$16.03 is trading 35.8% above its estimated GF Value™ of S$11.80.
GuruFocus considers Haw Par to be Significantly Overvalued.
Key valuation signals for SGX:H02:
EPS (Basic): S$1.20
GF Value™: S$11.80 vs. price of S$16.03 (35.8% above fair value)
No single metric tells the full story. See the SGX:H02 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Haw Par Corp Ltd is a drug manufacturing company that operates multiple brands. The company is to expand its core businesses through product brand extension, strategic alliances, and exploring potential acquisitions. Its operating segments include the Healthcare segment, Investments segment, Property segment, and Leisure segment. The company generates the majority of its revenue from the Healthcare segment. Its Healthcare segment manufactures and distributes topical analgesic products under the Tiger Balm and Kwan Loong brands. Geographically, it generates key revenue from the other ASEAN and other Asian countries.
95GF Score
Get the complete analysis for SGX:H02
EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SGX:H02 has been successfully added to your 
